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Abstract 
Introduction: 
Prevention of mother-to-child-transmission of HIV is a priority public health problem 
in Africa as pregnant women and their children are the most vulnerable. In South 
Africa, a prevention of mother to child transmission of HIV (PMTCT) programme 
has been implemented in antenatal clinics to reduce paediatric HIV/AIDS. It is 
necessary to assess the uptake of this programme by pregnant women. 
 
Objectives 
The purpose of this study was to determine the uptake of the PMTCT programme in 
the antenatal clinics of Sedibeng district. Using data coming from all the antenatal 
clinics (ANC) at a primary health care levelin Sedibeng for 2005 and 2006, we 
determined the proportion of ANC attendees who accepted to be counselled, the 
proportion of these who accepted to be tested for HIV, the proportion of these who 
came back for results and the proportion who were HIV positive. Nevirapine (NVP) 
uptake was determined as well among HIV positive women and babies born to HIV 
positive women.  
 
Methods 
Data collection was by a record review of PMTCT records from all antenatal clinics 
in the district. To determine maternal uptake of PMTCT, data were extracted from 
antenatal clinics monthly collation sheets for 2005 and 2006. Nevirapine uptake for 
the babies born to HIV positive mothers was determined in one facility: data were 
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collected in the midwife obstetric unit of the community health centre from both the 
Nevirapine register and the mothers’ delivery records.   
 
Results 
A total of 8010 women attended in Sedibeng antenatal clinics in 2005 and 10217 in 
2006. In 2005 95 % of attendee women accepted to be counselled among whom 91% 
accepted to be tested for HIV. In 2006 93% women accepted to be counselled among 
whom 91% accepted to be tested. Almost all tested women came back for results: 
99% came back for results in 2005 and 98% in 2006. The proportion of HIV positive 
women in the attendees population was 23% in 2005 and 24% in 2006. Nevirapine 
was dispensed to only 600 per 1000 HIV positive women in 2005 and 539 per 1000 
HIV positive women in 2006. From June 2005 to May 2006 only 59% of babies born 
to an HIV positive mother received NVP. 
 
Discussion and conclusion 
The study showed a good uptake of voluntary counselling and HIV testing in 
Sedibeng district antenatal clinics. But a low proportion of HIV positive women and 
HIV-exposed babies received NVP. There was probably a loss of follow up of 
women between ANC visits and delivery. Nevirapine uptake must be improved in 
Sedibeng antenatal clinics and further investigations need to be done to understand 
the factors influencing uptake.   
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1/ Introduction  
1.1 Background 
HIV/AIDS is an important public Health problem in the world today, especially in 
Africa (1). In 2007, the number of people living with HIV/AIDS in Sub-Saharan 
Africa was estimated at 22 million persons (2). In sub-Saharan Africa HIV prevalence 
decreased from 5.8% in 2001 to 5% in 2007, but it is still by far the highest in the 
world. In 2005, there was 5.5 of people living with HIV/AIDS in South Africa (1). 
Women are the most affected by the epidemic, representing 61% of the HIV positive 
adults (2). Antenatal HIV surveillance in South Africa estimates that 28% of pregnant 
women were HIV positive in 2007 (3). The prevention of paediatric HIV is therefore 
a priority. 
 
Worldwide there were 2.5 million HIV positive children in 2007 (2), most of them 
from Sub-Saharan Africa (2). Mother-to-child-transmission (MTCT) of HIV is 
considered to be responsible for 90% of childhood HIV (4). The risk of MTCT of 
HIV without any interventions is 5-10% during pregnancy 10- 20% during delivery 
and 5-20% during breast feeding (4). This risk can be reduced to 2% with an adequate 
intervention (4). Different treatments have been tested around the world to define 
how to prevent the mother-to-child-transmission of HIV (5-8). It appears that this 
transmission could be reduced significantly with better detection of HIV during 
pregnancy, better care of HIV positive pregnant women, prophylactic antiretroviral 
therapy and avoiding breast-feeding (8, 9). In 2005 the MTCT of HIV was under 2% 
in the developed countries while it was up to 20% in Africa (10, 11). In Africa, 
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PMTCT rates vary between countries: in Nigeria, a transmission rate was found at 
45% (12), In Cameroon and Uganda, lower transmission rates were found at 11% and 
18.3% with a  treatment (13, 14). In South Africa, the national transmission rate of 
HIV to infant was estimated at 21% in 2006 (15). A Study in Abidjan shows that this 
rate could be reduces to 2-4% with adequate PMTCT programme (16).  
 
The HIV positive patient’s care, and the improvement of maternal and child care have 
become priorities in South Africa, and the government has developed guidelines for a 
comprehensive HIV and AIDS programme, with specific action on children’s care 
and HIV prevention (17). The National Department of Health has also developed 
guidelines to implement a specific Prevention of mother-to-child-transmission 
(PMTCT) programme for South Africa (8). This programme includes the detection of 
HIV positive women at the antenatal clinics through voluntary counselling and 
testing (VCT) for HIV; and HIV positive mothers who accept to be in the programme 
receive Nevirapine which they are required to self-administer at the onset of labour. 
Children born from HIV positive women are given Nevirapine after birth (8). At the 
time of this study, the provision of HAART to pregnant women had recently been 
recommended as the primary strategy for all eligible HIV positive pregnant women, 
to ensure the health of the pregnant women as well as her baby (18).  
 
This Nevirapine protocol has been shown in different studies to reduce transmission 
of HIV from the mother to baby by almost 50% (11, 19-22) and is cost effective (19, 
23, 24). In South Africa this NVP protocol has recently be replaced by a combination 
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of AZT and NVP in the national recommendations (18). The PMTCT programme in 
South Africa also includes specific protocols for safe delivery practices, the mother‘s 
education about safe infant feeding options and risks, and the provision of free milk 
formula to women who choose this option. Current guidelines require children 
exposed to HIV to be tested at 6 weeks with PCR, and to be followed up until 12 
months of age (18).  
 
1.2 Statement of the problem.  
PMTCT programmes have been implemented in many settings around the world. 
South Africa PMTCT implementation started with two pilot sites in each of the nine 
provinces in 2001 (25). From those sites, there was a great development of PMTCT 
services, with 22% of all health facilities in the public sector providing PMTCT 
services by 2004 (4, 26). These sites are financed by a conditional grant each year, 
but the regions also utilise their own budget to develop the PMTCT programme (27). 
PMTCT programmes have been shown to be effective to decrease perinatal 
transmission of HIV and to improve children’s outcomes (11, 28-30). But, wide 
coverage of PMTCT programme, and high uptake of the programme are important to 
achieve success (31, 32). Therefore it is important to ensure wide availability of 
PMTCT services and to ensure women’s acceptance of the programme and their 
consent to participate in VCT, which is the entry point of PMTCT programme.  
 
However, there are a number of challenges to the provision of PMTCT services, 
particularly in Africa. The lack of trained and skilled staff in the PMTCT sites, due to 
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human resources constraints, threatens availability of PMTCT services in many 
countries in Africa (32, 33). The main problems faced to implement the PMTCT 
policy in South Africa were lack of personnel and unsuitable infrastructures (25). 
 
Many factors could influence the uptake of PMTCT services where these are 
available (31-35). The quality of voluntary counselling has an influence on the 
women’s acceptance of the test (33, 36, 37), and using a rapid test and giving HIV 
results on the same day improves PMTCT uptake (33, 38). Socioeconomic status, 
community beliefs and availability of community support structures for HIV positive 
women can determine women acceptance of the programme (32, 33, 35, 39). 
Additionally the role of the partner may sometimes plays an important role in 
women’s choices about PMTCT use. For example women can be afraid to be tested 
without a partner’s consent (33, 35). It has been shown that couple counselling and 
partner’s involvement can improve HIV testing uptake (33). In some countries, like 
South Africa, fears and taboos around HIV are important, and can compromise a 
good uptake of PMTCT programmes (34, 40).  
 
In Gauteng province, the HIV prevalence among antenatal clinic users was estimated 
at 30,3% in 2007 (3). PMTCT services were first introduced in Gauteng in two pilot 
sites in 2001. After these pilot sites, many sites have been developed in Gauteng and 
PMTCT is now available in most health centres, including in the Sedibeng district in 
Region B of Gauteng where this study was done (25, 26). However, focusing on 
availability of PMTCT service is not enough. Ensuring high uptake of available 
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services is important but very little is really known about the uptake of PMTCT 
services by pregnant women. This study intends to determine PMTCT uptake in 
Sedibeng districts, in Gauteng, by determining the proportion of eligible women’s 
who utilise the different components of the PMTCT programme.  
 
1.3 Justification for the study 
To improve the implementation of the PMTCT programme, the Department of Health 
needs information about PMTCT coverage and PMTCT uptake by pregnant women. 
It is important to document service uptake, but the PMTCT programme sometimes 
suffers from the lack of data to allow a good analysis of the programme and its 
implementation in antenatal services (41). In Sedibeng, PMTCT data are routinely 
collected at antenatal clinics and submitted to the district, and then to the provincial 
health department where all health information is centralised. The data is often not 
analysed at the district level, and therefore there are missed opportunities to use it for 
programme review.  
 
It is important to ensure good quality of the data collected and collated at clinic and 
district level. Nurses at a clinic level also need to be motivated to collect and transmit 
complete and accurate data to the district health department (41). This will then 
improves the knowledge about service provision of the PMTCT programme. It is an 
important part of the fight against mother to child transmission of HIV (8). The 
uptake of counselling, HIV testing and Nevirapine use is not well known and 
documented for the Sedibeng as a whole and for Gauteng in general. Data that have 
  - 6   
been routinely collected at health centres and are available, but need to be collated 
and analysed to give useful information for monitoring programme implementation.  
 
1.4 Literature review 
HIV is a global burden, and the MTCT is a priority for HIV programmes everywhere. 
In developing countries, MTCT remains a major problem (42), especially in Sub 
Saharan where nearly 90% of the 2,5 millions of HIV positive children live (2). In 
2007 330 000 children in the world died because of HIV (2). This number could be 
drastically reduced by implementing effective PMTCT programmes. 
 
1.4.1 Elements of a PMTCT programme 
It is recommended that a PMTCT programme should include voluntary counselling 
and testing for HIV, antiretroviral therapy for the mother and the baby, and safe 
infant feeding (5-8). In South Africa, the PMTCT guidelines include more 
specifically (43): 
 A voluntary Counselling and testing (VCT) service 
 HIV test with Rapid HIV testing kit, which has shown its efficiency to 
improve the rate of women coming back for test results(33, 38) 
 Nutritional supplements for HIV positive women during pregnancy.  
 Single dose Nevirapine for mother in labour and child at the time of birth. 
(replaced recently by a dual therapy AZT+NVP (18))  
 Management of labour of HIV positive mothers in accordance with protocols.  
 Free breast milk substitute for six months for mothers choosing this option.  
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 Cotrimoxazole for babies of HIV positive mothers for six months after birth.  
 Periodic follow-up of mother and baby to ensure well being.  
 Testing of the baby at one year to establish HIV-status.  
 
Counselling for HIV testing has two parts: Pre-test counselling and post-test 
counselling. During pre-test counselling, the counsellor gives information about HIV, 
propose an HIV test and explain the benefit of the PMTCT programme for a child’s 
outcome when the mother is HIV positive (7). During post-test counselling HIV 
results are given back and the counsellor emphasises the benefit of Nevirapine to 
decrease the risk of HIV transmission to the baby, explains how to use it and explains 
the benefits and risks of different infant feeding options, and the alternative feedings 
available to avoid MTCT after birth. (8) 
 
1.4.2 Prophylactic antiretroviral therapy against MTCT of HIV 
Prophylactic antiretroviral therapy is an important part of the PMTCT programme. 
The first study showing the efficacy of AZT to significantly reduce HIV transmission 
by 67% was published in 1994 (9). In the developed countries, a long term AZT 
protocol has been used with really good results (9, 11). According to WHO if there is 
an indication for an antiretroviral therapy in pregnancy, this must be the priority to 
secure the woman’s health. According to guidelines, clinical staging and CD4 counts 
must be done during pregnancy to assess the HIV positive woman’s eligibility for 
HAART (10, 18). Currently the standard of care in many developed countries is to 
provide HAART to all HIV positive pregnant women. As a result of these 
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interventions, MTCT rates are now less than 2% in these countries (10). South 
African guidelines indicate that women with CD4 of less than 200 or a clinical stage 
IV will receive HAART (18).  
 
In the absence of HAART, WHO recommends azidothymine (AZT) from 28 weeks 
of pregnancy, AZT and lamivudine (3TC) and a single dose of Nevirapine during 
delivery, and AZT and 3TC for 7 days in postpartum, while the baby receive NVP 
and AZT for one week after birth (10).  
 
HAART is not widely available in many developing countries, and the more complex 
PMTCT protocols are expensive and require good follow-up and health system 
support (10). It has therefore been difficult to implement these in the developing 
countries and so cheaper regimens such as a single dose Nevirapine (NVP) which is 
less demanding on women and health service resources have been used (10). NVP 
allows an easier implementation of the PMTCT programme compared to other 
antiretroviral protocols, and can be realistically used in resources limited settings (44, 
45). It is relatively cheap, and thus allows the South African government to deliver it 
for free in the public sector (23, 24, 27). Single dose Nevirapine has proven its 
efficacy to prevent mother-to-child transmission of HIV. Clinical trials have shown 
that single-dose of NVP can reduce transmission from mother to child by almost 50% 
(11, 19, 20). It reaches a high blood concentration with a single oral dose, allowing a 
good protection during delivery, and it has a long half time, having a detectable level 
in maternal blood and breast milk 3 weeks after delivery (46).  
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Resistance to Nevirapine can appear after this short regimen (47, 48), but studies 
show that it neither compromises a future antiretroviral therapy for the mother, nor 
prevention of mother to child transmission of HIV during a further pregnancy (45, 49, 
50). Single dose of Nevirapine presents no significant toxicity, and can be safely used 
(46). NVP is however not as efficient as other short course regimens combining AZT 
+/- 3TC +/- NVP (6, 51, 52). In South Africa, NVP was the standard of care at the 
time of the study, however at the beginning of 2008 the NVP protocol was replaced 
by dual therapy combining AZT and NVP to the mother and the baby (18). This dual 
therapy regimen, which is now the standard care for PMTCT in all public sector 
health facilities shows a better efficacy than NVP alone (10).  
 
1.4.3 Experience of PMTCT in the developing countries 
In Africa, PMTCT implementation has faced many challenges, because countries 
have less information, infrastructural and human resources and money. For example 
in South Africa, PMTCT implementation was constrained by a lack of skilled staff 
and inadequate infrastructure (25). To ensure PMTCT success, it is therefore 
important to consider factors that influence availability of PMTCT as well as those 
that influence women’s willingness to participate to PMTCT programmes. While the 
former is key, this literature focuses on the latter, as this has the most relevance for 
this study. 
 
Where PMTCT programmes are available, uptake of these services has not been as 
high as anticipated (25, 39, 53). Cultural and socio-economical factors, such as the 
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level of education or socio-economical status, influence women’s willingness to be 
part of the PMTCT programme (35, 39, 53), as do traditional beliefs and stigma 
around HIV (34, 40). The lack of knowledge about HIV and pregnancy is also an 
important barrier to uptake (53). Gender also plays a role as women may be barred 
from participating in PMTCT due to gender norms and their subordinate role in 
society or due to fear of disclosure to their partner as a result of unequal power 
relations (30, 39, 53).  
 
Voluntary counselling and testing uptake in PMTCT settings 
VCT is the entry-point to the PMTCT programme. Therefore, it is important to 
ensure high utilisation of VCT by pregnant women, in order to optimise PMTCT 
uptake. Evaluation of the first 18 PMTCT sites in South Africa in 2001 and 2002 
showed a lot of differences in VCT uptake among provinces among provinces (25). 
The country’s average acceptance rate for HIV testing was 51% in 2001 varying 
among facilities from 17% to 90%, and 56% in 2002 varying from 14 to 92% (25, 26, 
54).  In Gauteng, the first PMTCT pilot sites were in Natalspruit and Kalafong 
hospitals. In these sites HIV prevalence among ANC pregnant women was 29.4%. 
The VCT acceptance rates were there respectively 68% and 23% in 2001, and 80 % 
and 61% in 2002. These data highlight variations in uptake between PMTCT sites 
within provinces. These intra-provincial variations are further highlighted by a study 
conducted in Gauteng at the Coronation women and children’s hospital in February 
2002. which showed that 95% of women attending to ANC services were tested for 
HIV (55).  
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The quality of counselling is an important factor and is linked to HIV testing uptake 
(7, 8). Pre-test counselling needs enough staff and well-trained counsellors and a 
physical space which allows privacy (26). Staff shortages are an important barrier to 
provision of good counselling. In Gauteng province, to avoid the adverse 
consequences of the lack of personnel on the availability and quality of counselling, 
lay counsellors were trained to complement existing staff (26). These measures 
improved the availability and quality of pre-test counselling, by providing more staff 
available with good counselling skills (26, 54). The importance of counselling was 
further highlighted in the South African pilots sites evaluation; a 90% HIV test 
acceptance rate in Kwazulu natal, almost twice the country’s average was attributed 
to good counselling (54).  
 
Elsewhere in Africa, studies show often a good VCT uptake. An international survey 
done on 13 sites, 12 of them in Africa, in the late 1990s showed that the VCT 
acceptance rates were over 70% in 12 of 13 sites (30).  Others studies showed 
acceptance rates over 70% or sometimes over 90% (30, 56-60). In Zimbabwe a recent 
study showed a low VCT acceptance rate at 55% (36). It appeared that 79% of the 
interviewed women would have accepted the test in an opt-out strategy (36). In an 
opt-out strategy the HIV test is routinely part of a standard package with usually no 
separate written consent, but the patient has the right to refuse it (opt-out), whereas an 
opt-in strategy is a client initiated testing or counselling, with a written consent 
provided (33). 
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HIV results uptake 
A good counselling intends not only to encourage women to test for HIV, but also to 
come back for results and enter the PMTCT programme if they are HIV positive. 
However many counselled and tested women do not return for their HIV results. In 
South Africa, only 53% women received their results in the Natalspruit pilot site in 
2002. In Kalafong, the return rate was good at 93% in 2002 (26). In Coronation 
Women and Children’s hospital all HIV positive women received their results back 
(55). Elsewhere in Africa, a study aggregating results from 13 countries found that 
the overall rate of return for HIV was 92% (61). In Nairobi a study comparing the 
HIV rapid test to HIV Elisa test found that 96% of women had their results back with 
a rapid test whereas the return rate was 73.3% with the Elisa test (38). Factors that 
increase the rate of women coming back for results include: results being given on the 
same day, using HIV rapid test (24, 38, 53) and availability of well-skilled staff to 
provide pre test counselling (33, 36, 37).   
 
Nevirapine uptake during delivery 
In PMTCT programmes every HIV positive woman should be dispensed an 
appropriate medication such as NVP to prevent mother-to-child-transmission of HIV. 
PMTCT coverage is important to ensure a good NVP uptake. In Malawi this was 
highlighted in as study where only 45% of HIV positive women and 34% of their 
babies received NVP. Many women delivered in a facility without any PMTCT 
programme implemented (59); 63% of HIV positive women were missed because 
PMTCT programme was not implemented everywhere (59). If their state of disease 
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doesn’t need to be treated by HAART, they will be provided NVP to be taken just 
before delivery. Their baby will receive NVP after birth. A good NVP uptake is 
essential to allow a significant decrease of mother-to-child-transmission of HIV in 
resources limited settings (16). However the proportion of exposed babies who 
receive NVP is low (less than 50%) in several settings outside South Africa (56, 61).  
 
Identifying the determinants of PMTCT uptake is important to inform the 
development of appropriate interventions. A comprehensive analysis of the factors 
affecting PMTCT uptake is however beyond the scope of this proposed study. But as 
a starting point, this study intends to describe available PMTCT services in Sedibeng 
district of Gauteng province and to determine pregnant women’s uptake of the 
PMTCT programme in primary health care facilities. The study will use data that has 
been collected routinely at antenatal clinics and midwife obstetric units located within 
all the primary health care facilities. 
 
1.5 Aim 
This study will assess PMTCT uptake by pregnant women at primary care level 
(community health centres and clinics) in the Sedibeng district of region B in 
Gauteng, for the period 2005-2006. The PMTCT sites include antenatal clinics and 
midwife obstetric units, thus allowing analysis of data from antenatal period up to 
delivery.    
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1.6 Objectives 
With respect to primary care facilities in Sedibeng district, the objectives were to: 
1. Determine the proportion of women attending ANC that accepted voluntary 
counselling for HIV testing during 2005 and 2006. 
2. Determine the uptake of HIV testing after the pre-test counselling in ANC during 
2005 and 2006. 
3. Determine the proportion of women coming back to post-test counselling and 
collecting HIV test results. 
4. Determine the proportion of women with a positive HIV result who were dispensed 
Nevirapine during the antenatal period. 
5. Determine the proportion of babies of HIV positive women that received 
Nevirapine after birth. 
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2/ Methodology 
In this chapter, the methodology is described, including the study design, the study 
population and the variables and indicators chosen to determine the five study 
objectives. It also describes challenges encountered during data collection and the 
limitations of using retrospective review of facility records for data collection for 
research.  
 
2.1 Study design 
It was a cross sectional descriptive study involving a retrospective review of records. 
Collated data had been collected from antenatal clinics and midwife obstetrics units 
located within all community health centres and clinics in Sedibeng district during 
two years (2005 and 2006) for the first four objectives, and from one community 
health centre for the period from June 2005 to May 2006 for the fifth objective. These 
data were analysed to determine the uptake of PMTCT services in the district. 
 
2.2 Setting 
There are 38 antenatal clinics in Sedibeng providing PMTCT services, 33 of these are 
at the primary care level. Only facilities providing PMTCT at a primary care level 
were selected for this study. The facilities were a mix of small clinics, located 
sometimes in really poor areas and bigger clinics in urban areas (Annexure A). 
PMTCT was implemented in all these sites following the recommendations from the 
South African Health department and they all use rapid HIV tests (8). The first part 
(objectives 1 to 4) of the study included all primary care facilities in the district 
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(community health centres and clinics). The second part of the study (objective 5) 
included PMTCT data from Johan Heyns community centre, an urban facility with a 
mid-wife obstetric unit where deliveries are performed. 
 
According to key informants at the health facilities, women enter the PMTCT 
programme through VCT at antenatal clinics. A woman coming for antenatal visits is 
counselled and tested for HIV during the first visit (usually during the first trimester) 
or during the following visits if she refuses to be tested. All facilities use rapid tests. 
After being tested, women get their results back the same day and have a post test 
counselling. If they are HIV positive, they are offered the opportunity to be part of 
the PMTCT programme. This includes physical examination for clinical staging of 
their disease, assessment of CD4 count, and HIV triple therapy (HAART) if they are 
eligible (CD4 count less than 200 cells/mm3 or WHO stage IV) Women who are not 
eligible for HAARTfor their own health AZT at 28 weeks and are dispensed 
Nevirapine during the 28th week ANC visit and are counselled about how and to take 
NVP at the onset of labour. Nevirapine dispensed to women in the ANC is recorded 
on a Nevirapine register. There is a time lag between the diagnosis of an HIV positive 
status and dispensing of NVP; while HIV testing results are given at various times 
during pregnancy, usually after the first ANC visit, Nevirapine is always given at the 
28th week visit. Thus a woman who tests HIV positive during the first trimester visit 
will only be given NVP three months later.  
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Patients’ data are captured by nurses during the antenatal visits on a consultation 
sheet (Annexure B). At the end of each month the nurses collated all this information 
on a monthly collation sheet which is submitted to the district manager to be included 
in district health information system office (Annexure C).  
 
Women usually deliver in a different facility, as only hospitals and community health 
centres with a MOU unit conduct deliveries. In Johan Heyns mid-wife obstetric unit 
(MOU), nurses ask the women who come in labour whether they had VCT during 
their ANC visits, whether they accepted the HIV test, and what is their HIV status. 
They record this information on the patient held card, which is retained by the MOU 
after the delivery. If the woman doesn’t know her HIV status, she is offered VCT, 
and NVP is dispensed to her if she tests HIV positive. Nevirapine is taken by the 
women herself, but nurses give Nevirapine to the baby after delivery and record it in 
the Nevirapine register.  
 
2.3 Study population 
No sampling was done, so all the clinics and community health centres that provide 
ANC were included (Annexure A). All routinely collected PMTCT records at the 
ANC facilities for 2005 and 2006 were included in the analysis. To determine the 
first three objectives, all monthly collated PMTCT records for 2005 and 2006 
obtained from the district health information system (DHIS) were included in the 
analysis.  
 
  - 18   
The fourth objective was to determine the uptake of Nevirapine during labour among 
HIV positive pregnant women. The study population was supposed to be all entries in 
the MOU delivery register. However because of a poor record-keeping in the labour 
ward, we instead used the PMTCT registers from the antenatal clinics as the study 
population to determine the NVP dispensed to women at antenatal visits during 2005 
and 2006.  
 
For the fifth objective, we choose to work only in Johan Heyns CHC because it was 
not possible to link women who tested HIV positive at ANC to delivery records. The 
study population for this objective included all MOU files (delivery ward records) 
which were filled in for all women who delivered in the MOU in Johan Heyns 
community health centre from June 2005 to May 2006, as well as the patient held 
cards which were kept by the MOU department after delivery.  
 
2.4 Measurement 
For the first three objectives data were extracted from the DHIS monthly collation 
sheets (Annexure C) using data extraction sheets that were developed for this study 
(Annexure D). There were some missing data as not all the facilities submitted data to 
the DHIS every month. It was not relevant to study each facility separately, so 
individual facility data were aggregated for the whole district for each month. Data 
were missing for April, July, August and December 2005, and January and part of 
February 2006.   
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The following variables were extracted from the data sheets using a data extraction 
sheet (Annexure D) for each year to determine objectives 1, 2 and 3 for Sedibeng 
district:  
-Number of new ANC attendees 
-Number of women consenting to voluntary counselling. 
-Number of women voluntary testing for HIV. 
-Number of HIV positive women.  
-Number of post counselled women. 
-Number of women who were dispensed with Nevirapine during ANC. 
 
The original intention for objective 4 was to determine the proportion of HIV positive 
women who took NVP during labour, but this variable couldn’t be determined from 
the mid-wife obstetric unit records because women that came to deliver with their 
Nevirapine already with them were not routinely recorded in the register. No 
information was available about Nevirapine taken in most of the individual patient 
files, and so it was possible to determine the Nevirapine use only for a few HIV 
positive women. A NVP register was used by MOU nurses to record HIV positive 
women who were given NVP when arriving for delivery. But the same Nevirapine 
register was used by the antenatal clinic as well, so both populations from the ANC 
clinic (those to whom NVP were dispensed during ANC) and MOU (those who were 
given NVP during labour) were collated in one list. So, due to the limitation of the 
data recording system, this indicator could not be determined. Therefore, the variable 
used in this study as a proxy for NVP uptake was: Nevirapine dispensed during 
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antenatal visits. This variable is routinely recorded in the DHIS, although it is 
acknowledged that this indicator does not measure actual use of NVP by HIV 
positive women. This represents the number of ANC attendees who tested HIV to 
whom Nevirapine was dispensed at the 28th week ANC visit. This indicator was 
measured as an aggregate for all facilities (Annexure D). However the limitation is 
that there is a time lag between HIV test results and NVP dispensing and so for a 
given month it was not the same population of women who tested HIV positive that 
month and who received NVP. So to estimate NVP use in this study, the ratio women 
who received NVP to women who tested HIV positive was determined for 2005 and 
2006 (not calculating a proportion as it is not possible to link the NVP doses 
dispensed to the denominator).  
 
The fifth objective was studied in a single midwife obstetric unit to allow assessment 
of activities at delivery. To determine the fifth objective, two variables were 
measured using data from the mothers’ files from the MOU and the register of babies 
receiving NVP in the labour ward:  
-number of HIV positive women delivering in the MOU 
-number of babies who were given Nevirapine 
 
In the MOU at Johan Heyns community health centre there wasn’t any register of 
HIV positive women who had delivered in the mid wife obstetric unit. HIV status is 
recorded on the patient held card which is kept with the patient record after delivery. 
A coding system is used to preserve anonymity. To determine the number of HIV 
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positive women, all patient held cards were reviewed and HIV status was confirmed 
by means of the clinic’s coding system. As there were a lot of incomplete records at 
the beginning of 2005, prior to implementation of the coding system, this review 
included the period June 2005 to May 2006 to cover twelve calendar months. Babies 
who received Nevirapine were listed in the Nevirapine register. They were registered 
under their mother’s record number, and it was possible to link them to their mother. 
For each women found positive in her files, we checked in the NVP register if the 
baby had received Nevirapine.  
 
2.5 Data processing and analysis 
Data were entered and processed using Excel. Descriptive statistics (proportions and 
ratios) were used to determine all the indicators. Data were summarised using 
descriptive statistics: mean and standard deviation for numerical data and proportion 
and ratios for categorical data. The uptake of PMTCT was analysed by three different 
levels, through the following indicators, which were calculated per month and 
aggregated at a district level:  
2.5.1 Uptake of counselling and testing 
1. Percentage of women antenatal attendees who accepted to be pre-test 
counselled 
 Number of women accepting pre-test counselling 
 Number of women attending to the antenatal clinic  
 
 

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2. Percentage of pre test counselled women who accepted to be tested for HIV 
 Number of women accepting to be tested for HIV 
 Number of women who had pre-test counselling  
 
 3.a Percentage of women tested for HIV who came back for results 
Number of women coming back for result and post-test counselling 
 Number of women who had an HIV test  
3.b Percentage of women counselled who came back in post-test counselling 
Number of women coming back for result and post-test counselling 
 Number of women pre-test counselled 
 
4. HIV prevalence among women who accepted to be tested for HIV 
Number of HIV positive women 
  Number of women who had an HIV test 
 
These indicators allowed the researcher to determine the uptake of various 
components of the PMTCT service.  
 
 




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2.5.2 Uptake of Nevirapine by pregnant women 
The use of Nevirapine by HIV positive women attending ANC could not e 
determined directly (as described above). However, the following indicator was 
estimated for the whole district for one year period:  
 Number of women who were dispensed NVP 
 Number of HIV positive ante-natal clinics attendees 
 
This indicator allowed the researcher to determine the Nevirapine dispensed to HIV 
positive women in Sedibeng, as a proxy from NVP uptake.  
 
2.5.3 Uptake of Nevirapine in babies born to HIV positive mothers 
Descriptive statistics were used to summarise data, and one indicator only was 
studied in Johan Heyns mid-wife obstetric unit: 
 Number of babies receiving Nevirapine 
 Number of babies born from HIV positive mothers  
 
This indicator allowed the researcher to determine the uptake of Nevirapine among 
babies exposed to known HIV positive women in this mid-wife obstetric unit.  
 
 
 
 


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2.6 Ethical considerations 
This research protocol was submitted to the committee for research on human 
subjects (medical) of the University of the Witwatersrand and approved. The study 
began after the approval by the ethics committee. Authorisation to undertake the 
study in Sedibeng was also obtained from the Health Department. Data used to 
determine objectives 1, 2, 3 and 4 came from the district health information system 
and were anonymous. To determine objective 5 no names and only records numbers 
were used to identify HIV positive women and link HIV positive mother to their 
babies. A coding system was used in these records to denote HIV status. Results were 
then aggregated for each month and only the number of HIV positive women and the 
number babies receiving NVP were used in the study data. No individual clinic 
names are included in this report.  
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3/ Results 
This chapter presents the results of the study. Results from different facilities in 
Sedibeng are aggregated and presented here in line with the study objectives. The 
results presented in this report need to be interpreted regarding the limitations of the 
data sources. However these are useful results for management as they are based on 
the best available routine health data available in the district.    
Table 1 below presents the data that were available for analysis in this study. 
 
 
Table 1: data available for analysis in 2005 and 2006 in Sedibeng antenatal 
clinics
 
N/A: Not Available (missing data) 
 
 
2005 Number of 
sites 
 Numbers of 
ANC 
attendees 
(first time 
visit) 
2006 Number of 
sites 
  Numbers of 
ANC 
attendees 
(first time 
visit) 
January 25 818 January N/A  N/A  
February 20 990 February 20 762 
March 24 1007 March 27 1329 
April N/A  N/A  April 24 917 
May 25 1014 May 24 995 
June 27 1138 June 24 1017 
July N/A  N/A  July 25 1135 
August N/A  N/A  August 29 1205 
September 22 1217 September 27 993 
October 27 1217 October 20 1016 
November 17 609 November 11 425 
December N/A  N/A  December 14 423 
  - 26   
 
 
3.1 ANC attendees and uptake of pre test counselling  
With a varied number of facilities participating every month, the denominator 
(number of ANC attendees) was variable during the year. The number of antenatal 
clinics participating was between 11 and 29 with ANC attendees ranging from 423 
attendees in December 2006 to 1329 attendees in March 2006. 
 
The percentage of women accepting to be counselled was high among the ANC 
attendees, with few variations during the year. The proportion of ANC attendees 
accepting counselling per month varied between 91% and 99% (Table 2). Over-all, 
across the district in 2005, 95% of antenatal clinic attendees accepted to be pre test 
counselled, and in 2006 96% accepted to be pre test counselled (table 2). 
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Table 2: Women who accepted pre-test counselling among the antenatal clinic 
attendees in Sedibeng antenatal clinics: 2005-2006 
  
 Numbers of 
ANC attendees 
(first time visit) 
Number of women 
who had pre-test 
counselling  
%  of women accepting 
pre-test counselling 
Jan-05 818 762 93 
Feb-05 990 930 94 
Mar-05 1007 985 98 
May-05 1014 938 93 
Jun-05 1138 1109 97 
Sep-05 1217 1192 98 
Oct-05 1217 1129 93 
Nov-05 609 599 98 
total 2005 8010 7644 95 
Feb-06 762 725 95 
Mar-06 1329 1301 98 
Apr-06 917 888 97 
May-06 995 981 99 
Jun-06 1017 1001 98 
Jul-06 1135 1084 96 
Aug-06 1205 1182 98 
Sep-06 993 947 95 
Oct-06 1016 922 91 
Nov-06 425 408 96 
Dec-06 423 414 98 
Total 2006 10217 9853 96 
  - 28   
 
3.2 Uptake of HIV testing 
The percentage of women who accepted to be tested is high with few variations 
during the two years studied: ranging from 88% to 97% (table 3). As shown in table 
3, 91% of pre test counselled women accepted to be tested in 2005, and 93% in 2006. 
 
Table 3: Women who accepted to be tested for HIV after pre-test counselling in 
Sedibeng antenatal clinics: 2005-2006. 
  
Number of women 
who had pre-test 
counselling 
Number of voluntary 
HIV testing 
% of women accepting 
to be tested in the 
population of women 
counselled 
Jan-05 762 717 94 
Feb-05 930 848 91 
Mar-05 985 911 92 
May-05 938 838 89 
Jun-05 1109 972 88 
Sep-05 1192 1085 91 
Oct-05 1129 1026 91 
Nov-05 599 543 91 
total 2005 7644 6940 91 
Feb-06 725 672 93 
Mar-06 1301 1214 93 
Apr-06 888 834 94 
May-06 981 872 89 
Jun-06 1001 906 91 
Jul-06 1084 1000 92 
Aug-06 1182 1091 92 
Sep-06 947 907 96 
Oct-06 922 889 96 
Nov-06 408 396 97 
Dec-06 414 382 92 
Total 2006 9853 9163 93 
 
  - 29   
3.3 Uptake of Post test counselling 
The percentage of women coming back for post test counselling and collection of 
HIV results after voluntary testing is very high, ranging from 93% to 100%. The total 
number of tested women coming back for result was 99% in 2005 and 98 % in 2006 
and 89% and 85% of counselled women came back for post-test counselling and HIV 
results (table 4). 
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Table 4: Women coming back for results after counselling and testing in 
Sedibeng antenatal clinics: 2005-2006  
* February 2006: number of women post test counselled and number of women who 
were dispensed NVP were missing 
 
 
 
 
 
 
  
Number of 
women who 
had pre-test 
counselling 
Number of 
voluntary 
HIV testing 
Number 
women who 
had post-test 
counselling 
% of women coming 
back for results after 
testing 
% of women  
coming back for 
results after 
counselling 
Jan-05 762 717 696 97 91 
Feb-05 930 848 830 98 89 
Mar-05 985 911 911 100 92 
May-05 938 838 838 100 89 
Jun-05 1109 972 960 99 87 
Sep-05 1192 1085 1081 100 91 
Oct-05 1129 1026 998 97 88 
Nov-05 599 543 524 97 87 
total 2005 7644 6940 6838 99 89 
Feb-06 725   Missing     
Mar-06 1301 1214 1208 100 93 
Apr-06 888 834 833 100 94 
May-06 981 872 872 100 89 
Jun-06 1001 906 892 98 89 
Jul-06 1084 1000 927 93 86 
Aug-06 1182 1091 1054 97 89 
Sep-06 947 907 901 99 95 
Oct-06 922 889 889 100 96 
Nov-06 408 396 396 100 97 
Dec-06 414 382 373 98 90 
Total 
2006 9853 8491 8345 98 85 
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3.4 Percentage of HIV positive women 
The percentage of HIV positive women among first time ANC attendees ranged 
between 19% and 26% during 2005 and 2006 (Figure 1). The total number of ANC 
attendee women who tested HIV positive in 2005 and 2006 was respectively 23% and 
24%. Using the counselled women as the denominator, the percentage of HIV 
positive women among HIV tested women was included between 23% and 30% 
(Figure 2); and the annual figure was the same in 28% 2005 and 27% in 2006.  
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Figure 1: Representation of the percentage of HIV positive women among all 
women who attended to Sedibeng antenatal clinics in 2005 and 2006. 
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Figure 2: Representation of the percentage of HIV positive women among the 
women who were tested for HIV in Sedibeng antenatal clinics in 2005 and 2006. 
 
 
3.5 Uptake of Nevirapine 
3.5.1 Nevirapine dispensed compared to the number of HIV positive women 
Figure 3 shows that the amount of Nevirapine dispensed and the number of women 
who tested HIV positive at ANC visits don’t follow the same variations. The 
Nevirapine dispensed is always lower than the number of HIV positive women over 
the whole 2 years period. For the reasons explained in the methodology it was not 
possible to determine on a monthly basis the percentage of women testing HIV 
positive who were dispensed with NVP. Therefore we instead determined for each 
one year period the number of NVP doses dispensed to the number of women who 
tested HIV positive at ANC. As shown in table 5, a ratio of 600 per 1000 HIV 
positive women received NVP in total in 2005, and 539/1000 in 2006.  
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Figure 3: Representation of the numbers of women who received Nevirapine and 
those who tested positive to HIV in 2005 and 2006 in Sedibeng antenatal clinics. 
 
Table 5: Ratio of the number of HIV positive women to number of women who 
were dispensed Nevirapine during ANC visits in Sedibeng antenatal clinics: 2005 
and 2006.  
 
  Number of HIV 
positive women 
Number of NVP 
dispensed 
Women receiving NVP per 
1000 women who tested 
HIV positive per year 
Total 2005 1821 1094 600/1000 
total 2006 2402 1295 539/1000 
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3.5.2 Uptake of NVP in HIV-exposed babies 
This objective was studied only in the Johan Heyns community health centre’s MOU, 
and thus focuses only on the women who delivered in this facility. This data is not 
related to the data presented in previous sections which focuses on ANC attendees. 
Table 6 shows that based on labour ward records, amongst the population of women 
who delivered in this MOU during the period from June 2005 to May 2006, 32 % of 
women delivered with an unknown HIV status during the twelve months of the study 
and 15% refused the HIV test at the MOU. Women were categorised as with an 
unknown status when there was no information about their HIV status and HIV 
testing in their records or the patient held card. Women were categorised as having 
refusing the test when it was specified on their patient held card, meaning that MOU 
nurses proposed them an HIV test before delivery and they refused it.  
 
 
 
 
 
 
 
 
 
 
 
  - 35   
 
 
 
Table 6: HIV status of women who delivered in Johan Heyns mid-wife obstetric 
unit from June 2005 to May 2006.  
  
Number of 
women 
delivering in 
the MOU  
% that are 
HIV 
positive  
% that are 
HIV 
negative  
% who 
refused HIV 
testing 
% with no 
information 
on HIV 
status and 
testing  
total 
Jun-05 83 8 17 6 69 100 
Jul-05 78 13 30 6 51 100 
Aug-05 47 11 36 0 53 100 
Sept-05 93 17 38 26 19 100 
Oct-05 93 11 38 20 31 100 
Nov-05 77 17 51 15 17 100 
Dec-05 95 16 44 22 18 100 
Janv.-06 43 19 43 19 19 100 
Feb-06 90 14 44 16  26 
Mar-06 90 21 38 18  23 
Apr-06 99 15 39 10  36 
May-06 50 20 44 8  28 
Total 938 15 38 15  32 
 
The percentage of babies born to known HIV positive women delivering in Johan 
Heyns MOU that received Nevirapine varied during the year, ranging from 20% in 
August 2005, to 85% in February 2006 (table 7). A total of 56% of babies were given 
NVP during the one year period studied. 
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Table 7: Babies born to HIV positive women who received Nevirapine Johan 
Heyns mid-wife obstetric unit: 2005-2006. 
 
 
Number of HIV 
positive women who 
delivered 
Number of babies 
given Nevirapine 
% of babies who were 
given Nevirapine 
Jun-05 7 3 43 
Jul-05 10 7 70 
Aug-05 5 1 20 
Sep-05 16 9 56 
Oct-05 10 6 60 
Nov-05 13 6 46 
Dec-05 15 12 80 
Jan-06 8 5 63 
Feb-06 13 11 85 
Mar-06 19 12 63 
Apr-06 15 4 27 
May-06 10 7 70 
total 141 83 59 
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4/Discussion 
The aim of the study was to assess the PMTCT programme implemented in Sedibeng 
district in Gauteng: specifically its uptake by pregnant women attending ANC 
facilities at primary health care in the district.  
Voluntary counselling and testing uptake 
This study showed that the proportion of women accepting to be counselled was high 
in Sedibeng around 95% and 96% in 2005 and 2006. The proportion of women 
accepting to be tested among those who have been counselled was high as well, 91% 
and 93% for 2005 and 2006, respectively. HIV testing is essential to identify as many 
HIV positive pregnant women as possible. The quality of pre-test counselling is 
essential to convince women of the importance of testing for HIV, and being treated 
in case they are HIV positive (62). In Sedibeng during 2005 and 2006, almost all 
pregnant women attending ANC accepted to be tested for HIV. These results are an 
improvement compared to the pilots sites in 2002 in Gauteng, which showed 80% 
and 61% of women accepting to be tested for HIV respectively in Natalspruit and 
Kalafong (26).  
 
Other studies show similar results like in Cameroon and Zimbabwe where 100% of 
women were counselled (57, 63). In these studies 92.9% and 91.6% accepted to be 
tested respectively (63, 64). In Uganda, the proportion of women who accepted to be 
tested varied from really high (96%) in a rural hospital (65), to really low (25%) in 
another rural region (32, 61). One explanation of this really low acceptance rate was 
that only 56% of pregnant women attended facilities that provided PMTCT, as this 
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programme wasn’t implemented in all the ANC clinics (32).  A good uptake of pre-
test counselling in one facility is not sufficient to make an impact if the PMTCT 
programme coverage is low. In Sedibeng PMTCT is implemented in all the antenatal 
clinics in the public sector, indicating a good service coverage. In these facilities most 
women agreed to have a pre-test counselling for HIV. 
 
A good VCT implementation is important for a good PMTCT programme uptake. 
Pre-test counselling helps women to be aware of the importance of HIV testing for 
them and for their children. It fights the fears and stigmas which could prevent 
pregnant women from HIV testing (34, 62). Pre-test counselling needs to be done in 
good conditions, with adequately trained staff. It is essential for the PMTCT 
programme to reach as many women as possible. In a study comparing the proportion 
of HIV positive women who participate in the PMTCT programme to the ANC 
sentinel surveillance of HIV done in the same facilities, the percentage of HIV 
positive women who were not tested for HIV was estimated at 57% in Ethiopia and 
59% in Zimbabwe (66). It was then estimated that 618 child infections by HIV in 
Ethiopia and 1747 in Zimbabwe could have been averted if all HIV positive women 
had participated to the PMTCT programme.  
 
The percentage of first time ANC attendees who tested HIV positive in this study 
were 23% and 24% in 2005 and 2006 respectively. The proportion of HIV positive 
women identified through antenatal VCT is dependent on the HIV prevalence in the 
area studied. For example, a very high proportion of HIV positive women was found 
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in the western Kenyan region (47%) which is known to have one of the most highest 
HIV prevalence rates in Africa (57). A low proportion was found in Mombasa where 
only 14% of pregnant women were HIV positive (58). It was found to be 20% in 
Zambia (56) and Zimbabwe (63); and lower in Ivory Coast and Cameroon at 11.1% 
and 8.7% respectively (60, 64). In South Africa, a study done in Gauteng at the 
Coronation women and children’s Hospital in 2002 found a lower proportion at 18% 
than that found in our study (55). But pilot studies done in Kalafong and Natalspruit 
found a higher proportion at 29% in 2002 (26). The proportion of HIV positive 
pregnant women in our results is lower than the prevalence of HIV positive women 
reported by the Department of Health in Gauteng: 32.4% in 2005 and 30.8% in 2006 
(3). 
 
The percentage of women coming back for results was very high in this study at 98%. 
Quality of pre-test counselling and use of HIV rapid test are associated with good 
return rate (60, 62). Return rates were also high in other studies done in Africa. In 
Zambia and Zimbabwe they were at almost 100% (56, 63, 67). In the study assessing 
the South African pilots sites in 2002, the percentage of women who accepted HIV 
testing was high in some province like in Kwasulu Natal where it was around 90% or 
in the Western Cape, thanks to a good pre-test counselling (26). In other sites HIV 
testing uptake was much lower (around 50%), like in Mpumalanga or Northern Cape 
due essentially to a lack of counsellor (26). The percentage of women who received 
their results in this study in Sedibeng is higher than that observed in the initial 
PMTCT pilots sites in Gauteng in 2001 and 2002 (26). In Natalspruit pilot site only 
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53 % of tested women came back for results, due to a lack of good staff training and 
high workload (26).This study shows that a big proportion of women who attended 
ANC in Sedibeng primary health care facilities participated in the first important step 
of the PMTCT programme; that they were tested for HIV and returned for their 
results.     
Nevirapine uptake 
The data indicates that 600 pregnant women were dispensed NVP during 2005 per 
1000 HIV pregnant women who tested HIV positive during the same period; and in 
2006 this was 539 per 1000 HIV positive women. These data suggest that a 
significant number of women who tested positive during ANC weren’t dispensed 
NVP during ANC. This study also shows that only 59% of babies born to women 
known to be HIV positive at delivery at Johan Heyns MOU received NVP after birth. 
However, true NVP uptake is propably lower than this as only women with known 
HIV status were included in the determination of uptake. In actual fact, only 83 
babies out of 938 women (8.8%) who delivered at Johan Heyns CHC received NVP. 
A significant proportion of babies therefore should have, but did not, receive NVP to 
prevent MTCT, as the HIV prevalence amongst ANC attendees in this district was 
found to be 26%.  
 
Uptake of NVP by HIV positive women is the most essential step in PMTCT: unless 
a large proportion of HIV positive women utilise NVP during labour and NVP is 
given to their babies, there will be no impact on paediatric HIV. Despite the 
availability of counselling, uptake of NVP is not always optimal. In the South African 
  - 41   
pilot sites in 2002, the percentage of women who took Nevirapine during labour as 
prescribed varied within regions. It was 51% and 93% respectively in Natalspruit and 
Kalafong. At a national level 55% of women took NVP. This rate varied a lot within 
province and within month. In Northern Cape, for example, NVP delivered varied 
from 25% to 400% in one site. A poor quality of data was suspected to be responsible 
for this result (26). The proportion of babies who received Nevirapine was high in all 
facilities, with an overall at 99% (26). In Coronation Women and Children’s hospital 
in South Africa, 92% of HIV positive women received Nevirapine, among whom 
77% took it between 2 to 48 hours before delivery; and 79% of babies received 
Nevirapine (55). NVP uptake varies in different sites in Africa. In Zimbabwe, Kenya 
and Uganda studies found that over 70% of HIV positive women were given NVP 
(57, 63, 65). But in studies in Nairobi and Monbasa this percentage was lower at 15% 
and 20% respectively (29, 58).  
 
The uptake of NVP by HIV-exposed babies seen in this study is higher than that 
observed in other countries in Africa. For example, in Zambia only 40% of babies 
received NVP, and in a study collating six years of experience with PMTCT in 11 
countries only 44% of babies received NVP (56, 61). Among those sites, one site in 
Kenya showed an improvement in NVP uptake in babies by dispensing the 
Nevirapine syrup to the mothers at the same time that they were given Nevirapine 
tablets for themselves, and instructing them to give the syrup to their child within 
three days following delivery. As a result of this intervention, the percentage of 
babies receiving NVP in this site increased from 41% in 2003 to 76.5% in 2005 (61).  
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The purpose of the PMTCT programme is not only to detect HIV positive women, 
but to decrease the transmission of HIV from mother to child. This study shows that 
in Sedibeng, HIV positive pregnant women are well detected during the antenatal 
period, but Nevirapine uptake amongst these women is poor, meaning that the 
changes of the PMTCT programme being fully effective and reducing MTCT in this 
district are low. VCT acceptance is really good in this area, but it is useless if NVP is 
not delivered because HIV positive children will continue to be born despite a good 
VCT uptake and a good detection of HIV positive women during pregnancy.  
 
Similar experiences have been reported in other countries: for example, in Zambia 
and Malawi, a good VCT uptake was followed by a low NVP uptake by HIV positive 
women and their babies (56, 59). Loss to follow up could explain these observations; 
as observed in Malawi where an estimated 63% of HIV positive deliveries were 
missed (59). Women were followed well during ANC visits, and HIV testing and 
counselling were done, but there was a loss of follow up until delivery, as women 
usually delivered in another facility (59). In this study in Seidbeng, 93% women 
accepted to be tested, but more than a third of women arriving for delivery at the 
MOU unit had an unknown HIV status. Reasons for this observation need to be 
investigated through further research. However, in this setting it could have been due 
to a high workload with nurses forgetting to record the HIV status even though they 
had asked women about it. Stigmas and fears around HIV could also be a reason for 
them not to report HIV status on the file, as nurses could have been reluctant to ask 
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women about their HIV status and write it on their records or patient held card (34, 
40). Despite the use of a coding system nurses may be afraid of stigmatization and 
prefer not to write anything on the patients’ records or held card to protect anonymity 
(54). 
 
A high PMTCT coverage is important to ensure a good NVP uptake. In Malawi this 
was highlighted in a study where only 45% of HIV positive women and 34% of their 
babies received NVP. It was explained by the fact that many women delivered in a 
facility without any PMTCT programme implemented (59). This study went further 
by evaluating that 63% of HIV positive women were missed by the PMTCT 
programme because it was not implemented everywhere. Other reasons for a low 
NVP uptake were suggested: a time lag between the HIV test made at the beginning 
of the pregnancy and the dispensing of NVP to women later can partly explain a low 
NVP uptake, especially if it is associated with a loss of follow up (57, 58). Women 
who had received their HIV positive results didn’t come back to the antenatal clinic 
and were not dispensed NVP (57, 58).  
 
In our study time lag could explain a low NVP uptake; in the study clinics, HIV 
results are given early in the pregnancy, but NVP is given during the last ANC visit 
before delivery. If an HIV positive woman does not come back to the ANC later 
during her pregnancy she may not receive NVP even though she was tested in the 
ANC clinic. This is an important missed opportunity for prevention of MTCT. 
Further opportunities to prevent MTCT were missed in this study as 47% of women 
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arrived at the MOU for delivery with an unknown HIV status - 32% with no 
information on their records, and 15% because they refused the HIV test. All babies 
born to women with no HIV status information on their record did not receive NVP, 
and yet it is possible that many HIV positive women may have been misclassified as 
“unknown HIV status”.  
 
To ensure that HIV positive women who come in labour and their babies are given 
NVP some combined programmes offer NVP to all women who tested HIV positive 
and to all women with unknown status and to all these women’s babies (61). This 
method ensures that all HIV positive women and their babies receive NVP. But there 
is a small risk of toxicity, even though single dose of NVP has never been proven to 
have a high toxicity (46, 49). This method has two other disadvantages; it increases 
the cost of PMTCT by increasing NVP use, and it can undermine the promotion of 
VCT in the PMTCT programme. If women receive NVP, with small risk for them 
and their babies, HIV testing can appear useless as they will have prevention anyway. 
It can decrease the good acceptance rate of HIV testing in Sedibeng and the benefit of 
counselling not only in the PMTCT programme but for a more comprehensive HIV 
prevention (67). 
 
Another way to improve NVP uptake is to give the mother NVP tablet for her and 
NVP syrup for the baby at the time when delivering HIV positive results. In Western 
Kenya NVP was given to the mother at the same time as the HIV positive results, 
avoiding time lag and the risk of loss of follow up. It significantly increased the 
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percentage HIV positive women who were given NVP from 72.5% to 94.4% (61). 
Using the same method, this percentage was increased from 40.8% to 87.4% in a site 
in Cameroon (61). By giving the medication with the HIV results a bigger proportion 
of HIV positive women may be dispensed NVP.  
 
However, women who are given NVP do not always take it before delivery. There is 
no way to assess if pregnant women fully understand the NVP protocol and whether 
NVP is actually taken before delivery (57, 61). A study which tested the level of NVP 
in umbilical cord blood after delivery found that only 68% of women who were given 
NVP actually had taken it, as evidenced by presence of NVP in the cord blood (64). 
In some facilities, mothers are encouraged to take their NVP in the delivery ward in 
front of the staff to be sure that NVP was taken (66). In Sedibeng as well there is no 
way of knowing if the NVP was actually taken by women who received it during 
ANC visits and of evaluating HIV positive pregnant women’s knowledge of NVP and 
its use and benefits. Thus, strategies to improve the proportion of women who 
received NVP, should also improve the supervision of women around delivery, to 
ensure actual use.  
 
Factors influencing women’s uptake of available PMTCT programmes 
Various factors could influence women’s willingness to continue their participation in 
PMTCT programmes after being tested for HIV. In a study in Ivory Coast only 26.2% 
of HIV positive women followed the PMTCT programme (free PMTCT package 
including a NVP+ZDV prophylaxis) (60). In this study the VCT uptake was high 
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with almost 90% of women being tested and 73% post counselled. Among the HIV 
positive women who knew their status, only 35.8% accepted to be part of the PMTCT 
programme and receive a free medication (combination of Zidovudine and 
Nevirapine from 36 weeks to the birth). The main factors influencing women’s 
willingness to take AZT+NVP were the socio economical status, even though the 
medication was free, the education level, and the stigma and fears around HIV (60).  
 
The fear of disclosure to a partner has also a strong influence as single women were 
more likely to enter the PMTCT programme (53).  Different studies showed that 
these factors are responsible for the lack of involvement of women in the PMTCT 
programme (30, 60). The situation can be improved by involving partners in the 
PMTCT programme or with couple counselling. These measures increase the HIV 
testing uptake, and women are more likely to enter the PMTCT programme and take 
their medication while their partner is involved (33). The woman can fear 
stigmatization at a community level as well, where there are still stigmas, fears and 
taboos around HIV and prefer not to know about her HIV status, or hide it to nurses 
during delivery (34, 40).  
 
Challenges in evaluating PMTCT programmes 
 Many African countries have begun to implement PMTCT programmes but face 
many challenges both in programme implementation as well as monitoring progress 
and evaluating impact of these programmes. Assessing the uptake of PMTCT by 
pregnant women is a good way of monitoring progress with implementation. It is 
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important to find out the factors affecting uptake of PMTCT so that correct 
intervention can be put in place. Measuring the PMTCT programme effectiveness 
may however be challenging (68). Data used are collected from different registers 
which are not usually linked (68). It may be difficult to have the same denominator to 
compute different indicators such as the proportion of women accepting to be tested, 
the proportion of HIV positive women receiving Nevirapine, or the proportion of 
HIV positive women’s babies who received Nevirapine (68). PMTCT data could be 
used to determine the HIV prevalence among pregnant women, with a bias known 
that only women who accepted to be tested are included in the denominator 
population. But these data, coming from all the antenatal clinics, have the advantage 
to be available widely in all African countries (69).  Another challenge faced in 
evaluating PMTCT programme is that most of the time only the number of NVP 
tablets dispensed to women is recorded, with no guarantee that the mother took it 
during labour at the right moment to allow a full efficacy of the treatment (68).  
 
5/Limitations 
These results must be interpreted in the context of limitation of the study. The main 
limitation of this study was a poor quality of data. First of all, it was a record review, 
so the quality of data was directly linked to the way records were filled in. Monthly 
collation sheets were filled in by nurses at the end of each month in each facility. 
These data are completely dependant on the way nurses perceive them. If nurses 
don’t perceive these monthly collation sheets as a part of the district health 
information system and a way to improve their work, they will not fill them in as 
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seriously as they should, and the quality of data will be poor. Furthermore all the 
facilities didn’t report their sheets every month so there were various numbers of 
facilities participating in the study along the years. In the district health information 
system itself, data were missing for some entire months. We couldn’t have completed 
data for a whole year, bringing limitations to the results.  
 
The poor quality of data was a big limitation particularly in the determination of the 
fourth and fifth objective. For objective four, it is possible that some women may 
have not receive NVP during their ANC visit because they were already on HAART- 
it was not possible to ascertain this as this data is not recorded in the ANC clinic 
records. For onjective five, unfortunately 32% of the delivery records didn’t have 
information on the HIV status of the women who came for delivery. This affected the 
quality of our data, as in reality the percentage of babies exposed to HIV who 
received NVP may be lower as some women with unknown HIV status should have 
been included in the denominator; and some babies may have been born to HIV 
positive women but were not included in the study.  
 
The poor quality of data implies that we didn’t work on the whole population of HIV 
positive women at deliveyr, but only on those whose HIV status was reported on the 
files, which was around 70 %, with a possible selection bias. In Johan Heyns 
community health centre, nurses are responsible for giving NVP to HIV-exposed 
babies just after delivery. Again, poor quality data could partly explain the low NVP 
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uptake amongst HIV-exposed babies in this site as it is possible that NVP was given 
but not recorded.  
 
6/ Conclusion 
This study found that uptake of HIV voluntary counselling and testing was high in the 
antenatal clinics in Sedibeng. Almost all the women attending antenatal clinics at a 
primary care level were counselled and tested in Sedibeng district. A problem still 
remains in the NVP delivery to the mothers and the babies, which this study suggests 
is low. The quality of data is very poor but it seems that NVP is not given to all HIV 
positive women as it should be and is not given to all the babies born to HIV positive 
mothers who delivered in Johan Heyns Community Health Centre. The study also 
found that the district health information system has limitations that do not allow a 
good and accurate determination of the uptake of PMTCT at primary care level in 
Sedibeng district.   
 
7/Recommendations 
 
Low NVP uptake amongst HIV positive pregnant women and their babies is an 
important problem in the Sedibeng PMTCT programme. A number of measures are 
recommended to address some problems identified in this study. 
 
Loss of follow up seems to be an important problem: women’s follow up during 
pregnancy could be improved by linking MOU and ANC records in the district. This 
will allow health workers to identify women who tested HIV positive at ANC, and 
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who therefore need to take NVP during labour- this could reduce missed 
opportunities for preventing paediatric HIV.   
 
The proportion of women with a known HIV status at delivery could also be 
improved by strategies to fight stigma and fears around HIV testing and disclosure. 
This would increase pregnant women’s disclosure of their HIV status when they 
arrive in the MOU unit for delivery. Communities could be involved to promote 
PMTCT outside the ANC. Partners and/or family should also be more involved in the 
PMTCT programme. They could receive information about this programme and its 
importance within their community or they could be more involved in the pre-test 
counselling.  This could then increase the HIV positive women’s compliance to 
PMTCT by decreasing their fear of disclosure, and through the possible support from 
their relatives (30, 35, 60, 70).  
 
NVP uptake needs to be improved and further investigations must be done to test and 
understand possible mechanism for delivering NVP to pregnant women.  It can be 
improved by giving NVP at the same time as HIV positive results. For example, 
giving NVP to women at the same time as the HIV positive results would improve 
the proportion of HIV positive women dispensed NVP. This method could then offer 
NVP to both women who deliver in Sedibeng facilities and who deliver at home.  
 
Dispensing however does not mean the women will take the NVP during labour. 
Research is required to identify reasons why women may not take NVP when needed. 
  - 51   
But ensuring women are sufficiently educated and informed about when they have to 
take it and why is an important intervention that should be implemented. 
 
Training and information must be provided to nurses to make them understand the 
importance of asking all women their HIV status and reporting it systematically on 
the record. A third of the women records don’t have any information on the HIV 
status. An investigation must be done to understand. An investigation must be done in 
the MOU involving nurses to understand why they have difficulties to report HIV 
status even with an anonymous coding system.  
 
An improvement of the NVP management around delivery should also be done. 
Having to report it on the record, nurses would be less inclined to forget to ask about 
HIV status and to give NVP, even in high workload situations. After delivery nurses 
have to give NVP to the HIV positive mothers’ babies, and report it on the records. 
This indicator is dependant only on the nurses’ skills and willingness to follow the 
protocol. The percentage of NVP given to the babies and reported on the NVP 
register can be easily improved by improving skills and training of the MOU nurses.  
 
There is poor quality of data and this must be improved. ANC and MOU staff needs 
to be aware of the fact that good data is essential and records and registers should 
always be filled in correctly even during high workload situation. An improvement of 
the district health information system must also be done through investigation the 
data collection and collating process to understand its failures and improve it. A good 
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quality data allows a good analysis of the PMTCT programme and an improvement 
in the quality of service provided.   
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Annexures 
Annexure A 
 
List of the facilities including an antenatal clinic in Sedibeng district 
at a primary health care level 
 
 
SUBREGION EMFULENI 
Albertina Sisulu clinic 
Beverly hills clinic 
Boipatong clinic community health centre 
Boitumelo clinic clinic 
Bophelong clinic clinic 
Drieshoek clinic 
Empilisweni community health centre 
Evanton Main clinic 
helga khun clinic 
Johan Deo clinic 
Johan Heyns community health centre 
Levai Mbatha community health centre 
Market avenue Clinic 
Mpumelelo Clinic Clinic 
Quik shop Mobile 
Retswelapele Clinic 
Rustervaal clinic Clinic 
Sebei Z12 Clinic 
Sharpville community health centre 
Tshepiso Clinic 
Zone 13 Clinic 
Zone 3 Clinic 
 SUBREGION LESEDI 
 ext 7 Clinic 
Rathanda Clinic 
Rensburg C Clinic 
Ueckerman Clinic 
Usizolwethu Clinic 
Visckhuil 14 Clinic 
 SUBREGION MIDVAAL   
groedene Mobile 
Koorus Clinic 
Midvaal CHC community health centre 
Pontshong Clinic 
Rand vaal Clinic 
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 Annexure B 
Consultation sheet 
 
 
VCT (voluntary counselling and testing) 
Please tick the box provided 
NAME OF THE CLINIC  
DATE OF BIRTH 
 
OCCUPATION 
 
MARITAL STATUS 
 
PRE-TEST COUNSELLING Yes/No 
POST-TEST COUNSELLING Yes/No 
DATE COUNSELLED DATE COUNSELLED 
RAPID  
CONFIRMATION TEST  
ELIZA  
RESULT  REACTIVE  NON-REACTIVE  
REMARKS 
 
 
 
 
 
 
 
 
I HEREBY GIVE PERMISSION FOR BLOOD TO BE TAKENFROM ME  
WITH PURPOSE OF TESTING FOR HIV VIRUS 
SIGNATURE DATE 
NAME OF THE COUNCELLOR 
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Annexure C 
Monthly collation sheet 
 
 
NAME OF THE REGION:                                                 .   
NAME OF THE SITE:                                                       .    
DATE/YEAR/MONTH:                                                            . 
 
 
 
Week date No of ANC Attendees 
No of HIV 
women 
counselled 
No of women tested 
Number of 
Women HIV 
positive 
Number of 
women HIV 
negative 
NVP dispensed 
       
       
       
       
       
Total       
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Annexure D 
 Data extraction sheet 
 
 
Year Number of ANC 
attendees 
Number of women 
consenting to 
voluntary counselling 
Number of women 
voluntary testing 
for HIV 
Number of HIV 
positive women 
Number of post 
counselled women 
Number of women 
who were dispensed 
NVP 
January             
February             
March             
April             
May             
June             
July             
 August             
September             
October             
November             
 December             
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Annexure E 
 Ethics clearance certificate 
 
